public BRAFMutationAnalysisDetectedLynchSyndromeResult() { YellowstonePathology.Business.Test.IndicationLynchSymdrome indication = new IndicationLynchSymdrome(); this.m_Indication = indication.IndicationCode; this.m_IndicationComment = indication.Description; this.m_Interpretation = "BRAF mutation detected."; this.m_Method = YellowstonePathology.Business.Test.BRAFMutationAnalysis.BRAFMutationAnalysisResult.Method; this.m_Comment = "The results are compatible with a sporadic tumor and further genetic evaluation is not indicated."; this.m_References = YellowstonePathology.Business.Test.LynchSyndrome.LSERule.LSEColonReferences; }
public BRAFV600EKDetectedLynchSyndromeResult() { YellowstonePathology.Business.Test.IndicationLynchSymdrome indication = new IndicationLynchSymdrome(); this.m_Indication = indication.IndicationCode; this.m_IndicationComment = indication.Description; this.m_Interpretation = "BRAF mutation V600E detected."; this.m_Method = YellowstonePathology.Business.Test.BRAFV600EK.BRAFResult.Method; this.m_Comment = "The results are compatible with a sporadic tumor and further genetic evaluation is not indicated."; this.m_References = YellowstonePathology.Business.Test.LynchSyndrome.LSEResult.LSEColonReferences; }
public BRAFMutationAnalysisNotDetectedLynchSyndromeResult() { YellowstonePathology.Business.Test.IndicationLynchSymdrome indication = new IndicationLynchSymdrome(); this.m_Indication = indication.IndicationCode; this.m_IndicationComment = indication.Description; this.m_Interpretation = "The BRAF V600E status was tested on this colon tumor to rule out Lynch syndrome. Immunohistochemistry for MLH1 " + "and PMS2 showed loss of these proteins in the colon tumor. This can be either due to sporadic MLH1 methylation in the tumor or be related to a mutation in " + "MLH1 associated with Lynch syndrome. BRAF mutations are highly correlated with sporadic MLH1 methylation and have not been seen in Lynch associated colon " + "cancers. Therefore, the BRAF gene in the tumor was tested. The result is negative for BRAF V600E mutation in the tumor. The tumor should be tested for MLH1 " + "methylation to rule out Lynch syndrome."; this.m_Method = YellowstonePathology.Business.Test.BRAFMutationAnalysis.BRAFMutationAnalysisResult.Method; this.m_Comment = "Recommend testing for MLH1 methylation."; this.m_References = YellowstonePathology.Business.Test.LynchSyndrome.LSERule.LSEColonReferences; }
public BRAFV600EKNotDetectedLynchSyndromeResult() { YellowstonePathology.Business.Test.IndicationLynchSymdrome indication = new IndicationLynchSymdrome(); this.m_Indication = indication.IndicationCode; this.m_IndicationComment = indication.Description; this.m_Interpretation = "The BRAF V600E status was tested on this colon tumor to rule out Lynch syndrome. Immunohistochemistry for MLH1 " + "and PMS2 showed loss of these proteins in the colon tumor. This can be either due to sporadic MLH1 methylation in the tumor or be related to a mutation in " + "MLH1 associated with Lynch syndrome. BRAF mutations are highly correlated with sporadic MLH1 methylation and have not been seen in Lynch associated colon " + "cancers. Therefore, the BRAF gene in the tumor was tested. The result is negative for BRAF V600E mutation in the tumor. The tumor should be tested for MLH1 " + "methylation to rule out Lynch syndrome."; this.m_Method = YellowstonePathology.Business.Test.BRAFV600EK.BRAFResult.Method; this.m_Comment = "Recommend testing for MLH1 methylation."; this.m_References = YellowstonePathology.Business.Test.LynchSyndrome.LSEResult.LSEColonReferences; }